After spending billions of dollars on global acquisitions in recent years, private equity giant Fosun has begun to consolidate and focus on the performance of its many offshore assets as it tries to ease its heavy debt load, Caixin reports. In one such move, the company announced plans to spin off Israeli subsidiary Sisram Medical controlled by its pharmaceutical unit, for a listing in Hong Kong, according to a statement from Fosun International that was issued on Tuesday. Fosun and its affiliates set up Sisram in 2013 to acquire Israeli medical laser provider Alma Lasers. If the deal is completed, Sisram would become the first Israeli company to list in Hong Kong. The size of the proposed offering will be no less than 25% of Sisram’s total share capital, Fosun said, declining to give a fundraising target. After the listing, the company will remain a subsidiary of Fosun’s pharmaceutical unit, it said.